Geopacific Resources Limited (ASX:GPR) Announces High-Grade Auger Sampling Results
Geopacific Resources (ASX:GPR) reports significant high-grade gold results, extending surface mineralisation at its Woodlark Project.
Tag: Industry-Specific News
Peninsula Energy (ASX:PEN) Settles Samuel EPC Claims and Updates Lance Project
Peninsula Energy (ASX:PEN) settles Samuel EPC claims and provides updates on the Lance Project and key personnel changes.
Larvotto Resources (ASX:LRV) Reports High-Grade Gold and Antimony Drill Results
Larvotto Resources (ASX:LRV) announces high-grade gold and antimony results from its Eleanora-Garibaldi and Golden Gate drilling programs.
Nova Minerals (ASX:NVA) Commences Antimony-Gold Drilling at Stibium
Nova Minerals (ASX:NVA) begins a 3,000m antimony-gold drilling program at Stibium, aiming to establish maiden resource estimates.
Service Stream Limited (ASX:SSM) Secures Further nbn Fibre Upgrade Works
Service Stream Limited (ASX:SSM) secures a $440 million agreement with NBN Co to support further fibre upgrades.
Noxopharm Limited (ASX:NOX) Announces Positive Sofra™ Data from BioRay Collaboration
Noxopharm Limited (ASX:NOX) announces positive Sofra™ data from BioRay collaboration, validating its anti-inflammatory potential.
St George Mining Limited (ASX:SGQ) Starts Major Drilling at Araxá Project
St George Mining (ASX:SGQ) launches a 10,000m drilling campaign at the Araxá Project in Brazil to expand rare earth and niobium resources.
Ventia Services Group (ASX:VNT) Awarded $800M Fibre Upgrade Contract with NBN Co
Ventia Services Group (ASX:VNT) secures $800M contract with NBN Co to enhance Australia’s fibre network.
GenusPlus Group Ltd (ASX:GNP) Secures $130 Million NBN Contract
GenusPlus Group Ltd (ASX:GNP) secures a $130 million contract with NBN Co to upgrade fiber infrastructure across Western Australia.
PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.